FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to medicine, specifically cardiology, and concerns treating chronic cardiac failure. That is ensured by administering a pharmaceutical composition containing an activated potentiated form of very-low-dose angiotensin II receptor antibodies and an activated potentiated form of very-low-dose endothelial NO-synthase antibodies.
EFFECT: method provides improving quality of life and higher tolerance to physical loads in the given group of patients.
11 cl, 2 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CHRONIC HEART FAILURE AND PHARMACEUTICAL COMPOSITION FOR COMPLEX THERAPY OF CHRONIC HEART FAILURE | 2010 |
|
RU2525155C2 |
| METHOD OF TREATMENT AND PREVENTION OF ARTERIAL HYPERTENSION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ARTERIAL HYPERTENSION | 2010 |
|
RU2525156C2 |
| METHOD OF TREATING VEGETOVASCULAR DYSTONIA AND PHARMACEUTICAL COMPOSITION FOR TREATING VEGETOVASCULAR DYSTONIA | 2010 |
|
RU2523557C2 |
| METHOD FOR INCREASING PHARMACOLOGICAL ACTIVITY OF ACTIVE SUBSTANCE OF MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION | 2014 |
|
RU2572706C1 |
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2543331C2 |
| METHOD FOR INCREASE OF PHARMACOLOGICAL ACTIVITY OF ACTIVE AGENT OF DRUG PREPARATION AND PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2526153C2 |
| METHOD OF TREATING OBESITY AND ACCOMPANYING METABOLIC DISORDERS AND MEDICATION FOR TREATING OBESITY AND ACCOMPANYING METABOLIC DISORDERS | 2010 |
|
RU2552221C2 |
| METHOD OF TREATING OBESITY AND ASSOCIATED METABOLIC DISORDERS | 2013 |
|
RU2582393C2 |
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2543332C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2527689C2 |
